Intech Investment Management LLC lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 35.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 191,894 shares of the biotechnology company’s stock after selling 106,989 shares during the quarter. Intech Investment Management LLC owned 0.08% of Exelixis worth $11,209,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also added to or reduced their stakes in the business. Bessemer Group Inc. increased its holdings in shares of Exelixis by 22.1% in the third quarter. Bessemer Group Inc. now owns 2,418 shares of the biotechnology company’s stock worth $141,000 after buying an additional 437 shares during the period. Hantz Financial Services Inc. boosted its holdings in Exelixis by 7.3% during the 3rd quarter. Hantz Financial Services Inc. now owns 17,244 shares of the biotechnology company’s stock valued at $1,007,000 after acquiring an additional 1,170 shares during the period. Virtus Advisers LLC boosted its holdings in Exelixis by 16.8% during the 3rd quarter. Virtus Advisers LLC now owns 17,245 shares of the biotechnology company’s stock valued at $1,007,000 after acquiring an additional 2,476 shares during the period. Allworth Financial LP grew its position in Exelixis by 2.9% during the 3rd quarter. Allworth Financial LP now owns 10,864 shares of the biotechnology company’s stock worth $591,000 after acquiring an additional 302 shares during the last quarter. Finally, Fisher Asset Management LLC grew its position in Exelixis by 9.4% during the 3rd quarter. Fisher Asset Management LLC now owns 214,045 shares of the biotechnology company’s stock worth $12,502,000 after acquiring an additional 18,384 shares during the last quarter. 85.27% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the company. UBS Group set a $55.00 price objective on Exelixis in a research report on Monday, August 3rd. Citigroup reissued a “market outperform” rating on shares of Exelixis in a research note on Monday, October 19th. Barclays raised their target price on shares of Exelixis from $49.00 to $54.00 and gave the stock an “equal weight” rating in a report on Friday, October 30th. HC Wainwright lifted their target price on shares of Exelixis from $56.00 to $78.00 and gave the stock a “buy” rating in a research note on Monday, November 2nd. Finally, Zacks Research upgraded shares of Exelixis from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $58.62.
Read Our Latest Stock Report on EXEL
Exelixis Trading Down 2.8%
Exelixis stock opened at $67.10 on Tuesday. The firm has a market cap of $16.37 billion, a P/E ratio of 20.09, a P/E/G ratio of 1.80 and a beta of 0.45. Exelixis, Inc. has a 1-year low of $39.71 and a 1-year high of $73.69. The firm has a 50-day moving average of $62.45 and a 200-day moving average of $52.35.
Exelixis (NASDAQ:EXEL – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.05. The company had revenue of $658.70 million for the quarter, compared to the consensus estimate of $646.51 million. Exelixis had a return on equity of 45.54% and a net margin of 35.45%. Exelixis’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.78 EPS. Research analysts forecast that Exelixis, Inc. will post 3.42 earnings per share for the current fiscal year.
Exelixis Company Profile
Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.
Read More
- Five stocks we like better than Exelixis
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
